GTS Securities’s Filana Therapeutics FLNA Stock Holding History

GTS Securities’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30,336	Closed	-$601K	–	4087
2023 Q2	$744K	Buy	+30,336	New	+$731K	0.02%	527

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

GTS Securities's FLNA Position: Q3 2023 in Review

GTS Securities sold out of Filana Therapeutics (FLNA) in Q3 2023, closing a stake of 30,336 shares — an estimated $601K sold.

GTS Securities first reported a position in FLNA in Q2 2023 and held it in 1 quarter. The position peaked at $744K in Q2 2023. 140 funds tracked by Wall St. Rank hold FLNA as of Q3 2023.

GTS Securities reported no remaining Filana Therapeutics position as of Q3 2023 after selling out during the quarter.
GTS Securities sold 30,336 Filana Therapeutics shares in Q3 2023, an estimated $601K.
GTS Securities first reported a position in Filana Therapeutics in Q2 2023 and held it in 1 quarter.
GTS Securities's Filana Therapeutics position peaked at $744K in Q2 2023.
140 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2023.

Based on GTS Securities's 13F filing for Q3 2023, filed 15 Nov 2023.